The North Star Asset Management Inc. decides to keep it stake in Teva Pharmaceutical Industries Ltd. (TEVA) to the level of $447,000

The North Star Asset Management Inc. decides to keep it stake in Teva Pharmaceutical Industries Ltd. (TEVA) to the level of $447,000

North Star Asset Management Inc. continued to hold its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,355 shares of the company’s stock at the end of the second quarter. North Star Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $447,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Investec Asset Management LTD boosted its stake in Teva Pharmaceutical Industries by 112.4% in the first quarter. Investec Asset Management LTD now owns 2,171,655 shares of the company’s stock worth $116,205,000 after buying an additional 1,148,997 shares during the last quarter. Bridger Management LLC purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth approximately $59,320,000. Renaissance Technologies LLC boosted its stake in Teva Pharmaceutical Industries by 123.7% in the first quarter. Renaissance Technologies LLC now owns 1,191,263 shares of the company’s stock valued at $63,744,000 after buying an additional 658,763 shares during the last quarter. UBS Asset Management Americas Inc. boosted its stake in Teva Pharmaceutical Industries by 26.1% in the first quarter. UBS Asset Management Americas Inc. now owns 3,015,673 shares of the company’s stock valued at $161,368,000 after buying an additional 624,629 shares during the last quarter. Finally, PGGM Investments boosted its stake in Teva Pharmaceutical Industries by 64.7% in the second quarter. PGGM Investments now owns 1,344,928 shares of the company’s stock valued at $67,556,000 after buying an additional 528,470 shares during the last quarter. 63.35% of the stock is currently owned by institutional investors.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded down 1.17% during trading on Wednesday, reaching $44.04. 2,921,460 shares of the company’s stock were exchanged. Teva Pharmaceutical Industries Ltd. has a 12-month low of $44.00 and a 12-month high of $66.55. The stock has a 50-day moving average price of $49.57 and a 200 day moving average price of $52.37. The company has a market capitalization of $40.25 billion, a P/E ratio of 29.42 and a beta of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.05. The business earned $5 billion during the quarter, compared to analysts’ expectations of $4.86 billion. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The company’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.43 EPS. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post $5.24 EPS for the current fiscal year.

Several research firms have recently issued reports on TEVA. Jefferies Group reduced their price objective on shares of Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating on the stock in a research report on Thursday, July 14th. RBC Capital Markets set a $71.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Sunday, September 11th. Mizuho reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, July 25th. Bank of America Corp. set a $72.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Saturday, October 1st. Finally, Leerink Swann reiterated an “outperform” rating and set a $66.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Tuesday, August 16th. Seven analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $66.98.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Related posts

Leave a Comment